Delayed allergy to acyclovir revealed by lymphocyte proliferation test

I Nostri OrariLun. - Sab. 10:00-19:00 Chiamaci al+39 375 540 9488E-Mailallergy.dralbanesi@gmail.comViale Japigia, 131/DBariMiodottore.itSiamo anche qui

Marcello Albanesi1, Attilio Di Girolamo1, Vincenzo Aresta1, Maria Pia Rossi1, Lucia Giliberti1, Tommasina Perrone2, Danilo Di Bona1, Maria Filomena Caiaffa3, Giorgina Specchia2, Luigi Macchia1

previousVaccination Strategies and Immunotherapy Against Influenza

nextCutting Edge: FcgRIII (CD16) and FcgRI (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic B16 Melanoma

Dal 2020 sono Dirigente Medico al Policlinico di Bari nel Dipartimento d’Urgenza e Trapianti d’Organo e sono il fondatore dello studio Medico Allergologico “Albanesi” (che fantasia nel nome!)

Messaggi recenti

21 Aprile 2023
Telemedicina
3 Marzo 2022
Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study

Delayed allergy to acyclovir revealed by lymphocyte proliferation test

Leave a Reply Cancel Reply

previousVaccination Strategies and Immunotherapy Against Influenza

nextCutting Edge: FcgRIII (CD16) and FcgRI (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic B16 Melanoma

Telemedicina

Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study

Maintenance-Phase Subcutaneous Immunotherapy with House Dust Mites Induces Cyclic Immunologic Effects

The interactions of therapeutic antibodies with Fc receptors

Association between autoimmune disease and cutaneous melanoma with regard to melanoma prognosis

Messaggi recenti

Telemedicina

Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study

Link Utili